Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

NCT00024557 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Glioma
Glioblastoma Multiforme
Anaplastic Astrocytoma
Mixed Oligoastrocytoma
Malignant Astrocytoma

Interventions

DRUG: IL13-PE38QQR
PROCEDURE: targeted fusion protein therapy
PROCEDURE: surgery

Sponsor

INSYS Therapeutics Inc